Mizeracki A[Author] - Search Results

Year	Number of Results
2000	2
2001	2
2002	1
2004	1
2008	1
2011	1
2013	1
2014	1
2016	3
2021	1
2024	0

1

Singla S, Hu C, Mizeracki A, Mehta JL. Singla S, et al. Among authors: mizeracki a. Ther Adv Cardiovasc Dis. 2011 Dec;5(6):305-14. doi: 10.1177/1753944711429715. Epub 2011 Nov 16. Ther Adv Cardiovasc Dis. 2011. PMID: 22089475 Free article. Review.

2

Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.

Flatt DM, Brown MC, Mizeracki AM, King BJ, Weber KT. Flatt DM, et al. Among authors: mizeracki am. JAMA Cardiol. 2016 Aug 1;1(5):607-12. doi: 10.1001/jamacardio.2016.1878. JAMA Cardiol. 2016. PMID: 27434136 Review.

3

Next-generation airbags and the possibility of negative outcomes due to thoracic injury.

Khouzam RN, Al-Mawed S, Farah V, Mizeracki A. Khouzam RN, et al. Among authors: mizeracki a. Can J Cardiol. 2014 Apr;30(4):396-404. doi: 10.1016/j.cjca.2014.01.002. Epub 2014 Jan 8. Can J Cardiol. 2014. PMID: 24680170 Review.

4

Intraventricular Flow Patterns in Patients Treated with Left Ventricular Assist Devices.

Rossini L, Braun OÖ, Brambatti M, Benito Y, Mizeracki A, Miramontes M, Nguyen C, Martinez-Legazpi P, Almeida S, Kraushaar M, Vu V, May-Newman K, Bermejo J, Adler ED, Kahn AM, Del Alamo JC. Rossini L, et al. Among authors: mizeracki a. ASAIO J. 2021 Jan 1;67(1):74-83. doi: 10.1097/MAT.0000000000001158. ASAIO J. 2021. PMID: 33346993

5

Risk of stent thrombosis with bioresorbable vascular scaffolds.

Shah R, Ramos-Bondy B, Mizeracki A. Shah R, et al. Among authors: mizeracki a. Lancet. 2016 May 7;387(10031):1903. doi: 10.1016/S0140-6736(16)30413-5. Lancet. 2016. PMID: 27203646 No abstract available.

6

LOX-1 deletion and macrophage trafficking in atherosclerosis.

Ding Z, Mizeracki AM, Hu C, Mehta JL. Ding Z, et al. Among authors: mizeracki am. Biochem Biophys Res Commun. 2013 Oct 18;440(2):210-4. doi: 10.1016/j.bbrc.2013.09.020. Epub 2013 Sep 12. Biochem Biophys Res Commun. 2013. PMID: 24036126

7

A unique microvascular phenotype shared by juvenile hemangiomas and human placenta.

North PE, Waner M, Mizeracki A, Mrak RE, Nicholas R, Kincannon J, Suen JY, Mihm MC Jr. North PE, et al. Among authors: mizeracki a. Arch Dermatol. 2001 May;137(5):559-70. Arch Dermatol. 2001. PMID: 11346333

8

Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.

Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JW, Reinisch JF, Marchuk DA. Walter JW, et al. Among authors: mizeracki a. Genes Chromosomes Cancer. 2002 Mar;33(3):295-303. doi: 10.1002/gcc.10028. Genes Chromosomes Cancer. 2002. PMID: 11807987

9

GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas.

North PE, Waner M, Mizeracki A, Mihm MC Jr. North PE, et al. Among authors: mizeracki a. Hum Pathol. 2000 Jan;31(1):11-22. doi: 10.1016/s0046-8177(00)80192-6. Hum Pathol. 2000. PMID: 10665907

10

Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma.

North PE, Waner M, James CA, Mizeracki A, Frieden IJ, Mihm MC Jr. North PE, et al. Among authors: mizeracki a. Arch Dermatol. 2001 Dec;137(12):1607-20. doi: 10.1001/archderm.137.12.1607. Arch Dermatol. 2001. PMID: 11735711

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year